Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence

Jayachandran, Muthukumaran; Qu, Shen

doi:10.1002/med.21742

Cited by 53 publications

(51 citation statements)

References 74 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperuricemia (HUA) is a metabolic disease caused by abnormal purine metabolism or insufficient uric acid (UA) excretion, characterized by elevated UA in the blood (Borghi, 2017;Dehlin et al, 2020). Previous studies report that HUA is highly related to hypertension, hyperlipidemia, fatty liver, diabetes, and other diseases (Wang et al, 2014;Jaruvongvanich et al, 2017;Jayachandran and Qu, 2020;Kielstein et al, 2020). With improvement of people's living standard and change of dietary pattern, incidence of HUA is increasing in recent years (Liu et al, 2014;Singh et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway

Chen

Jiang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Sonneratia apetala Buch-Ham., an exotic mangrove species with antidiabetic, antibacterial, and antioxidant capacities, mainly distributes in the southeast coastal areas in China. The present work investigated the protective effects of Sonneratia apetala leaves and branches extraction (SAL) on hyperuricemia (HUA) in mice. Potassium oxonate (PO) and hypoxanthine (HX) were used to establish the HUA model by challenge for consecutive 7 days. Results revealed that SAL inhibited the increases in kidney weight and index compared to the vehicle group. Meanwhile, SAL significantly decreased the levels of uric acid (UA), creatinine (CRE), and blood urea nitrogen (BUN) in serum. Additionally, SAL inhibited the activity of xanthine oxidase (XOD) in the liver. SAL ameliorated PO- and HX-induced histopathological changes. Moreover, it regulated oxidative stress markers including malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD) activity, and glutathione (GSH) content. Also, SAL inhibited the increases in renal levels of interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-1β (IL-1β), tumor necrosis factor (TNF-α), monocyte chemotactic protein 1 (MCP-1), and transforming growth factor-β (TGF-β). SAL remarkably reduced suppressor of cytokine signaling 3 (SOCS3), Janus kinase 2 (JAK2), and subsequent phosphorylation of signal transducer and activator of transcription 3 (STAT3) expression. In addition, SAL inhibited the activation of nuclear factor kappa-B (NF-κB) in the kidney. Furthermore, SAL protected against HUA by regulating renal UA transporters of organic anion transporter (OAT1), urate reabsorption transporter 1 (URAT1), and glucose transporter 9 (GLUT9). These findings suggested that SAL ameliorated HUA by inhibiting the production of uric acid and enhancing renal urate excretion, which are related to oxidative stress and inflammation, and the possible molecular mechanisms include its ability to inhibit the JAK/STAT signaling pathway. Thus, SAL might be developed into a promising agent for HUA treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway

Chen

Jiang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“… 36 T2DM and hyperuricemia have been identified as an important risk factor for atherosclerosis. 11 , 22 However, whether sitagliptin treatment affects CIMT in T2DM patients with hyperuricemia has not been revealed. Although many clinical studies have shown that serum uric acid levels are correlated with CIMT, a marker of subclinical atherosclerosis, few studies have been conducted in patients with T2DM.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, hyperuricemia is also considered an independent risk factor associated with atherosclerosis. 22 Although studies have shown that type 2 DM (T2DM) patients with high uric acid levels have a higher risk of cardiovascular events. 23 But the PROLOGUE study has not demonstrated other clinical benefits of sitagliptin, and whether sitagliptin has different effects on CIMT in T2DM patients with hyperuricemia is unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study

Zhao

Wang

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background and Aims: Studies have shown that dipeptidyl peptidase-4 (DDP-4) inhibitors have anti-atherosclerotic effects. However, in the PROLOGUE study, sitagliptin failed to slow the progression of carotid intima-media thickness (CIMT) relative to conventional therapy. We conducted a post hoc analysis of the PROLOGUE study and compared the effects of sitagliptin and conventional therapy on changes in CIMT in subgroups with or without hyperuricemia. Methods: The PROLOGUE study was a randomized controlled trial of 442 patients with type 2 diabetes mellitus (T2DM). Patients were randomized to receive sitagliptin added therapy or conventional therapy. Based on the serum uric acid levels of all study populations in the PROLOGUE study, we divided them into hyperuricemia subgroup ( n = 104) and non-hyperuricemia subgroup ( n = 331). The primary outcome was changed in carotid intima-media thickness (CIMT) parameters compared with baseline during the 24 months treatment period. Results: In the hyperuricemia subgroup, compared with the conventional therapy group, the changes in the mean internal carotid artery (ICA)-IMT and max ICA-IMT at 24 months were significantly lower in the sitagliptin group [−0.233 mm, 95% confidence interval (CI) (−0.419 to 0.046), p = 0.015 and −0.325 mm, 95% CI (−0.583 to −0.068), p = 0.014], although there was no significant difference in the common carotid artery CIMT. Conclusion: The results of our analysis indicated that sitagliptin attenuated the progression of CIMT than conventional therapy in T2DM and hyperuricemia patients.

show abstract

“…Cardiovascular diseases (CVDs) are among the most common causes of death globally, with hyperlipidemia representing one of its main risk factors ( Mahdavi et al, 2020 ; Jayachandran and Qu, 2021 ). In Herman-Lara et al (2014) evaluation of the protective activity of micronized insoluble fiber from the bagasse of A. carambola as an ingredient of a functional food (FF) or as micronized insoluble fiber-rich fraction (IFRF) and its effects in vivo on lipid metabolism in a murine model, serum TG, TC, HDL-C, and LDL-C decreased after a murine model was treated with IFRF and FF, with corresponding inhibition rates of 14.2, 25.4, 55.06, and 12.18% by IFRF, and 30.18, 39.47, 35.11, and 43.18% by FF.…”

Section: Pharmacological Activitiesmentioning

confidence: 99%

Traditional Uses, Phytochemical Constituents and Pharmacological Properties of Averrhoa carambola L.: A Review

et al. 2021

View full text Add to dashboard Cite

Averrhoa carambola L. (star fruit) is an edible fruit that is extensively cultivated in southern China, Southeast Asia, India, and northern South America. It has a sweet and juicy taste and is frequently used in fruit salads and fruit platters, as a garnish in cocktail drinks and beverages, or squeezed into juice and served as a beverage. Traditionally, it has been used for treating diabetes and diabetic nephropathy, arthralgia, vomiting, lithangiuria, coughing, hangovers, and chronic paroxysmal headache for thousands of years. Currently, approximately 132 compounds have been isolated from A. carambola. Among them, flavonoids, benzoquinone, and their glycosides have been considered as biologically active substances, which are responsible for various biological activities. Pharmacological studies have revealed that crude extracts or monomeric compounds from A. carambola exhibit multiple bioactivities, such as anti-oxidant, anti-hyperglycemic, anti-obesity, anti-hyperlipidemic, anti-tumor, anti-inflammatory, hepatoprotective, cardioprotective, anti-hypertensive, neuroprotective, and others. Thus, A. carambola is a valuable treatment in Chinese medicine with therapeutic potential for multiple diseases, especially diabetes and diabetes-related diseases. Even though it is a very promising candidate in the development of functional food and the pharmaceutical industry, reports on its bioactivities have only been conducted in vivo and in vitro and there is a gap in research regarding clinical settings and safety. This review therefore provides a comprehensive and systematic overview of current progress on botany, ethnopharmacology, phytochemistry, pharmacology, and toxicity of A. carambola, providing a valuable reference for further developments and applications of A. carambola in the pharmaceutical industry and functional food.

show abstract

Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence

Cited by 53 publications

References 74 publications

The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway

The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway

Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study

Traditional Uses, Phytochemical Constituents and Pharmacological Properties of Averrhoa carambola L.: A Review

Contact Info

Product

Resources

About